Novartis

News

Sanofi’s oral BTK programme gets back on track

Sanofi has chalked up another win in a clinical trial of its oral BTK inhibitor rilzabrutinib, setting up regulatory filings in its first indication – rare disorder immune

News

Novartis names ex-BMS CEO Caforio as chair amid strong Q1

Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive

News

Novartis adds clinical-stage protein degrader from Arvinas

Novartis has accelerated its efforts to develop protein degrader therapies by licensing a prostate cancer candidate from Arvinas on the brink of starting phase 3 trials in

News

CHMP backs Novartis’ Fabhalta as first oral therapy for PNH

The March meeting of the EMA’s human medicines committee (CHMP) saw an approval recommendation for Novartis’ Fabhalta, on track to become the first oral monotherapy for ra

News

MS research network taps Seqster for data sharing

A research initiative in multiple sclerosis launched with support from Novartis has partnered with Seqster to provide a unified platform for data sharing, supporting patie

News

Sanofi trumpets win for oral BTK drug in chronic hives

Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a w

Sanofi’s oral BTK programme gets back on track

Novartis names ex-BMS CEO Caforio as chair amid strong Q1

Novartis adds clinical-stage protein degrader from Arvinas

CHMP backs Novartis’ Fabhalta as first oral therapy for PNH

MS research network taps Seqster for data sharing

Sanofi trumpets win for oral BTK drug in chronic hives

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Novartis

Editor's Picks